C9 and myasthenia gravis: Complement activation is one of the most significant pathogenic mechanisms of AChR-MG [86,87], and its role in the pathogenesis of MG is supported by histopathological findings of C3 and C9 deposits at the NMJ [86,88], as well as an increased in vitro uptake of complement C3b in serum [89].